indatuximab ravtansine (BT-062) - ImmunoGen, ADMA Biologics
Biotest: Annual Report 2014 (Biotest) - Mar 25, 2015 - Anticipated final clinical study result from P1/2 trial (NCT01001442) for monotherapy in multiple myeloma in Q2 2015 
Anticipated P1/2 data • Multiple Myeloma • Oncology
http://www.biotest.de/ww/en/pub/investor_relations/publications.cfm
 
Mar 25, 2015
 
.